BALAXI PHARMACEUTICALS LIMITED (BALAXI) — FY26 Annual Report | 31 July 2026(2 announcements)

Balaxi Pharmaceuticals Limited filed its Business Responsibility and Sustainability Report for FY 2025-26 on July 31, 2026, as part of its Annual Report. The standalone filing covers corporate governance, ESG disclosures, and sustainability practices. Key details include 100% export contribution, 6,251 total employees, and no manufacturing CAPEX. The report confirms compliance with environmental regulations and outlines risk factors like stricter climate policies affecting transport costs. The company emphasizes its asset-light model and global subsidiary structure, including recent acquisitions in Nicaragua. No dividend or financial performance metrics were disclosed in this filing.

Balaxi Pharmaceuticals announced its 83rd Annual General Meeting will be held on August 24, 2026 via video conferencing, with shareholders voting remotely on key resolutions including reappointment of directors and adoption of audited financial statements for FY 2025-26. The notice details e-voting procedures, proxy restrictions, and shareholder participation protocols through NSDL's platform, emphasizing compliance with SEBI and MCA regulations for remote engagement.